Viking Therapeutics Inc (NASDAQ:VKTX) has received a consensus recommendation of “Buy” from the twelve analysts that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year target price among brokers that have covered the stock in the last year is $22.54.

A number of equities analysts have recently commented on the stock. BidaskClub upgraded shares of Viking Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Wednesday, April 3rd. HC Wainwright restated a “buy” rating and set a $31.00 price objective on shares of Viking Therapeutics in a research note on Thursday, April 11th. William Blair restated an “outperform” rating on shares of Viking Therapeutics in a research note on Friday, March 29th. Svb Leerink upgraded shares of Viking Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the company from $10.00 to $21.00 in a research note on Friday, March 29th. Finally, Maxim Group cut their target price on shares of Viking Therapeutics from $28.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 14th.

Shares of Viking Therapeutics stock traded up $0.23 during trading hours on Tuesday, reaching $8.82. 2,801,634 shares of the company’s stock were exchanged, compared to its average volume of 4,643,337. Viking Therapeutics has a fifty-two week low of $3.69 and a fifty-two week high of $24.00. The company has a market cap of $635.29 million, a price-to-earnings ratio of -22.05 and a beta of 2.75.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Wednesday, March 13th. The biotechnology company reported ($0.07) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.03. Analysts expect that Viking Therapeutics will post -0.45 earnings per share for the current year.

A number of large investors have recently modified their holdings of the stock. BlackRock Inc. lifted its stake in Viking Therapeutics by 22.4% in the 4th quarter. BlackRock Inc. now owns 4,099,406 shares of the biotechnology company’s stock valued at $31,361,000 after purchasing an additional 749,505 shares during the last quarter. Vanguard Group Inc. lifted its stake in Viking Therapeutics by 21.4% in the 3rd quarter. Vanguard Group Inc. now owns 2,877,287 shares of the biotechnology company’s stock valued at $50,123,000 after purchasing an additional 508,097 shares during the last quarter. Vanguard Group Inc lifted its stake in Viking Therapeutics by 21.4% in the 3rd quarter. Vanguard Group Inc now owns 2,877,287 shares of the biotechnology company’s stock valued at $50,123,000 after purchasing an additional 508,097 shares during the last quarter. Park West Asset Management LLC lifted its stake in Viking Therapeutics by 31.8% in the 4th quarter. Park West Asset Management LLC now owns 1,672,507 shares of the biotechnology company’s stock valued at $12,794,000 after purchasing an additional 403,400 shares during the last quarter. Finally, Fiera Capital Corp acquired a new stake in Viking Therapeutics in the 4th quarter valued at about $11,167,000. Institutional investors and hedge funds own 65.35% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol.

Recommended Story: How can you know how many shares are floating?

Analyst Recommendations for Viking Therapeutics (NASDAQ:VKTX)

Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.